## 3 Results and Discussion
### Analysis of Plasmid Presence and Antibiotic Resistance Genes
#### 3.6.5 NRPS and PKS Gene Clusters
Furthermore, a one-to-one comparison with the funisamine BGC revealed the following identities: protein XIJ17350, resembling agmatinase, shares 65.7% identity with FunS1; protein XIJ17351, similar to ACP S-malonyltransferase, shares 44.5% identity with FunS3; protein XIJ17352, similar to acyl-CoA ligase, shares 57.8% identity with FunS2; and protein XIJ17361, similar to tryptophan 2-monooxygenase, shares 67.9% identity with FunA13. However, no notable gene clusters, including those related to sugar biosynthesis, were identified. Based on these findings, we tentatively infer that BGC 17 may be involved in the production of a very long-chain fatty acid, similar to funisamine. BGC Region 24 Derived from _Lentzea_ sp. JNUCC 0626  
The antiSMASH analysis of _Lentzea_ sp. JNUCC 0626 region 24 revealed a BGC comprising 41 genes, including a Type II polykteide synthase (PKS) along with a significant number of tailoring enzymes. As illustrated in Figure 8 and Table S31, a notable observation is that 28 out of these 41 biosynthetic genes exhibited homology to the trioxacarcin (Txn) biosynthetic genes from _S. bottropensis_, while two genes displayed sequence similarity to aromatic PKS genes found in nogalamycin (Sno) biosynthesis in _S. nogalater_[74; 75]. The remaining 11 genes within the BGC include IteE, which shares similarity with the TOMM precursor leader peptide-binding protein; IteX2, similar to a SagB/TheOx family dehydrogenase; IteG, homologous to a flavodoxin family protein; IteX3, related to the DinB family protein; IteX5, similar to NAD(P)H-binding proteins; IteW, which resembles an amino acid adenylation domain-containing protein; and IteR2 and IteR3, which are sensor histidine kinases. Additionally, there are three genes annotated as hypothetical proteins: IteX1, IteX6, and IteX7. Interestingly, genes commonly associated with sugar biosynthesis and glycosyltransferases, which are typically found in trioxacarcin and nogalamycin clusters, were absent in this region. Therefore, based on the genetic makeup of BGC region 24, we hypothesize the potential production of an aromatic polykteide structurally related to the trioxacarcin aglycone. BGC Region 33 Derived from _Lentzea_ sp. JNUCC 0626  
The antiSMASH analysis of BGC region 33 predicted a 77% structural similarity with the pacidamycinin BGC. Pacidamycin are uridyl tetra/pentapeptide antibiotics that act on the translocase MraY, inhibiting bacterial cell wall assembly, and they share structural similarity with napsamycin and sansanomycin. The pacidamycinin BGC encodes 22 proteins (PacA-V), including highly dissociated NRPS modules and various tailoring enzymes [76; 77; 78]. Allof these proteins share a common structural framework, where a (2S,3S)-diaminobutyric acid (DABA) residue acts as a connection point for the 3-deoxyuridine moiety via a 4,5-enamide linkage. As shown in Figure 9 and Table S32, region 33 comprises 26 ORFs (proteins XJ1J4076-XJ1J4100), exhibiting significant amino acid sequence similarity with the pacidamycin, sansanamycin, and napsamycin gene clusters [79; 80]. Specifically, 18 ORFs in this cluster show high amino acid homology with 18 ORFs from the pacidamycin BGC, excluding PamB (hypothetical protein), PamK (FAD-dependent oxidoreductase), PamL (peptide synthetase), and PamO (ATP-dependent adenylate). Additionally, protein XJ1J4078, which is not found in the pacidamycin BGC, shares sequence similarity with napsamycin NpsC and a hypothetical protein from the sansanamycin cluster, both of which belong to the exonuclease/phosphatase family. Notably, an additional copy of genes corresponding to PacA (PamA2) and PacD (PamD2) of the pacidamycin BGC was identified downstream of the Pam BGC. This suggests that, if the cluster extends to include PamA2 and PamD2, it could potentially consist of more than 39 ORFs. In conclusion, the translocae MraY, a key enzyme in bacterial cell wall assembly, remains an underexplored target for the development of novel antibacterial agents.